• About us
• Contact

Advertisement

Organisation › Details

ImmunoGen Inc. (Nasdaq: IMGN)

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRa-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. *

 

	Start	1991-01-01 existent
	Group	AbbVie (Group)
	Industry	MAb
	Person	Enyedy, Mark J. (ImmunoGen 201705 CEO before Genzyme 200803 President Genzyme Oncology)
	Region	Waltham, MA
	Country	United States (USA)
	Street	830 Winter Street
	City	02451-1477 Waltham, MA
	Tel	+1-781-895-0600
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	38,212,000 (revenues, total (2006/07) 2007-06-30)
	Profit	-18,987,000 (2007-06-30)
	Cash	41,200,000 (2008-03-31)
		* Document for »About Section«: Debiopharm International SA. (5/24/17). "Press Release: Debiopharm International SA Enters the Field of Antibody-Drug Conjugates through Acquisition of Phase II Asset from ImmunoGen". Lausanne.
		Record changed: 2024-01-18

Advertisement

More documents for AbbVie (Group)

• [1] MedinCell S.A.. (4/16/24). "Press Release: Medincell Enters into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies". Montpellier....
• [2] Armstrong, Annalee / Bayer, Max / Masson, Gabrielle [Fierce Biotech]. (12/22/23). "News: Fierce Biotech M&A Tracker 2023. BMS, AbbVie Drop Billions for Neuropsychiatry Biotechs"....
• [3] Temedica GmbH. (8/2/23). "Press Release: Temedica and AbbVie Germany Are Launching Digital Companion for Patients with Chronic Inflammatory Bowel Diseases"....
• [4] ADC Therapeutics S.A.. (11/1/22). "Press Release: ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer". Lausanne....
• [5] AbbVie Inc.. (10/20/22). "Press Release: AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline". North Chicago, IL....
• [6] Sosei Group Corporation (d/b/a Sosei Heptares). (8/2/22). "Press Release: Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases". Tokyo & Cambridge....
• [7] AbbVie Inc.. (3/1/22). "Press Release: AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio". North Chicago, IL....
• [8] Abingworth LLP. (9/15/21). "Press Release: Abingworth Strengthens Investment Team with New Appointments in the US and UK". London....
• [9] Mission Therapeutics Ltd.. (8/9/21). "Press Release: Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone- Mission Receives $20 Million Milestone payment". Cambridge....
• [10] Novartis AG. (3/22/21). "Press Release: Novartis Appoints Karen Hale as Chief Legal Officer". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.